Founded in 2013, Syntimmune is the world’s leader in the biology of the
neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.
Syntimmune’s lead program targets FcRn and its critical role in IgG homeostasis and disease.
On September 5, 2015, David Cornblath, M.D., Professor of Neurology at Johns Hopkins University School of Medicine, discussed Syntimmune’s FcRn-IgG blockade approach in his presentation (“Peripheral Neuropathies”) at the 2nd World Congress on NeuroTherapeutics.